1 Estcourt LJ,Stanworth SJ,Doree C,et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev,2016,11(11):CD010983. 2 Zhi L,Chi X,Gelderman MP,et al. Activation of platelet protein kinase C by ultraviolet light B mediates platelet transfusion-related acute lung injury in a two-event animal model[J]. Transfusion,2013,53(4):722-731. 3 Gerber DE,Segal JB,Levy MY. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopo- ietic stem cell transplantation:implications for VTE prevention[J]. Blood,2008,112(3):504-510. 4 Kreuger AL,Middelburg RA,Zwaginga JJ,et al. Clinical practice of platelet transfusions in haematooncology[J]. Vox Sang,2015,109(1):91-94. 5 de Vries R,Haas F:English translation of the Dutch Blood Transfusion guideline 2011[J]. Vox Sang,2012,103(4):363. 6 Kaufman RM,Djulbegovic B,Gernsheimer T. Platelet transfusion:a clinical practice guideline from the AABB[J]. Ann Intern Med,2015,162(3):205-213. 7 Stanworth SJ,Estcourt LJ,Powter G,et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers[J]. New Engl J Med,2013,368(19):1771-1780. 8 Wandt H,Schaefer-Eckart K,Wendelin K,et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies:an open-label,multicentre,randomised study[J]. Lancet,2012,380(9850):1309-1316. 9 Novotny V MJ. Prevention and management of platelet transfusion refractoriness [J]. Vox Sang,1999,76(1):1-13. 10 Bishop JF,Matthews JP,Yuen K,et al. The definition of refractoriness to platelet transfusions[J]. Transfution Med,1992,2(1):35-41. 11 Stanworth SJ,Hudson CL,Estcourt LJ,et al. TOPPS Study Investigators. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies:recurrent event analysis[J]. Haematologica,2015,100(6):740-747. 12 Slichter SJ,Kaufman RM,Assmann SF,et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage[J]. New Engl J Med,2010,362(7):600-613. 13 吴擘颋,唐群业,姚顶根,等. 部分血液病患者血小板输注无效原因分析与预防[J]. 中国输血杂志,2010,23(8):584-585. 14 刘桂芳,夏和凤,王丽霞. 106例血液病患者机采血小板输注疗效的影响因素分析[J]. 临床血液学杂志,2015,28(12):1059-1061. 15 杨眉,罗洪,舒彬,等. 1786例血小板输注的疗效分析[J]. 中国实验血液学杂志,2013,21( 4) :1038-1041. 16 Slichter SJ,Davis K,Enright H,et al. Factors affecting posttransfusion plateletincrements,platelet refractoriness,and platelet transfusion intervals in thrombocytop- enic patients[J]. Blood,2005,105(10):4106-4114. 17 Quaglietta A,Di Saverio M,Accorsi P,et al. Correlates of post transfusion platelet increments. AABB Annual Meeting and TXPO[J]. Transfusion,2009,49(3S):162A. 18 Triulzi DJ,Assmann SF,Strau-ss RG,et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia[J]. Blood,2012,119(23):5553-5562. 19 尤建国,宣恒报,李玉峰,等. 血液病患者机采血小板输注疗效及血小板抗体分析[J]. 中华血液学杂志,2007,28(9):635-636. 20 Rebulla P. A mini-review on platelet refractoriness[J]. Hematologica,2005,90(2):247-253. 21 Nahirniak S,Slichter SJ,Tanael S,et al. Guidance on platelet transfusion for patient with hypoproliferative thrombolytopenia[J]. Transfus Med Rev,2015,29(1):3-13. 22 Hod E,Schwartz J. Platelet transfusion refractoriness[J]. Br J Haematol,2008,142(3):348-360. 23 Stroncek DF,Rebulla P,Platelet transfusions[J]. Lancet 2007,370(9585):427-438. 24 Quaglietta A,Saverio MD,Lucisano G,et al. Development of the Platelet Efficacy Score (PEscore) to predict the efficacy of platelet transfusion in oncohematologic patients[J]. Transfusion,2017,57(4):905-912.